Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Debt (2016 - 2023)

Amicus Therapeutics filings provide 14 years of Total Debt readings, the most recent being $13.0 million for Q2 2023.

  • On a quarterly basis, Total Debt fell 32.5% to $13.0 million in Q2 2023 year-over-year; TTM through Jun 2023 was $13.0 million, a 32.5% decrease, with the full-year FY2022 number at $21.4 million, up 13.32% from a year prior.
  • Total Debt hit $13.0 million in Q2 2023 for Amicus Therapeutics, up from $12.7 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $147.8 million in Q2 2020 to a low of $8.9 million in Q4 2020.
  • Median Total Debt over the past 5 years was $19.8 million (2021), compared with a mean of $63.1 million.
  • Biggest five-year swings in Total Debt: skyrocketed 1609.23% in 2019 and later crashed 93.96% in 2020.
  • Amicus Therapeutics' Total Debt stood at $147.4 million in 2019, then crashed by 93.96% to $8.9 million in 2020, then skyrocketed by 112.36% to $18.9 million in 2021, then rose by 13.32% to $21.4 million in 2022, then tumbled by 39.28% to $13.0 million in 2023.
  • The last three reported values for Total Debt were $13.0 million (Q2 2023), $12.7 million (Q1 2023), and $21.4 million (Q4 2022) per Business Quant data.